Delta 9 Cannabis Inc. (DLTNF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Delta 9 Cannabis Inc. (DLTNF) trades at $0.01 with AI Score 42/100 (Grade C). Delta 9 Cannabis Inc. Market cap: $3.04M, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for DLTNF: DLTNF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates DLTNF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
DLTNF: the 1 perspectives are evenly split.
How is this calculated? →Delta 9 Cannabis Inc. (DLTNF) Healthcare & Pipeline Overview
Delta 9 Cannabis Inc. is a Canadian integrated cannabis company involved in cultivation, processing, distribution, and retail. With 35 retail stores across the Canadian Prairies, Delta 9 offers a range of cannabis products, including dried flowers, oils, and derivative products, catering to both medical and recreational markets.
What Is the Investment Thesis for DLTNF?
Delta 9 Cannabis Inc. presents a speculative investment opportunity in the evolving Canadian cannabis market. The company's integrated business model, encompassing cultivation, processing, distribution, and retail, offers potential for revenue generation across the value chain. However, with a negative profit margin of -24.6% and a negative gross margin of -3.4%, the company's profitability is a concern. Future growth hinges on expanding retail operations, optimizing production costs, and capitalizing on emerging cannabis product trends. Investors should closely monitor the company's ability to achieve profitability and navigate the competitive landscape. The company's P/E ratio is -0.05.
Based on FMP financials and quantitative analysis
DLTNF Key Highlights
- Delta 9 Cannabis Inc. operates as an integrated cannabis company, participating in cultivation, processing, distribution, and retail sales.
- The company owns and operates 35 retail stores under the Delta 9 brand name across the Canadian Prairies as of April 20, 2022.
- Delta 9's product portfolio includes dried cannabis flowers, pre-rolls, oils, and extracted products, catering to both medical and recreational markets.
- The company has a negative profit margin of -24.6% and a negative gross margin of -3.4%, indicating profitability challenges.
- Delta 9's beta of 1.13 suggests that the stock is more volatile than the market average.
Who Are DLTNF's Competitors?
DLTNF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are DLTNF's Key Strengths?
- Integrated operations across the cannabis value chain.
- Established retail presence in the Canadian Prairies.
- Proprietary grow pod technology.
- Delta 9 brand recognition.
What Are DLTNF's Weaknesses?
- Negative profit margin and gross margin.
- Limited geographic presence compared to larger competitors.
- Reliance on the Canadian cannabis market.
- Small market capitalization.
What Could Drive DLTNF Stock Higher?
- Expansion of retail operations to new locations.
- Development and launch of new cannabis products.
- Potential changes in cannabis regulations in Canada.
- Announcement of strategic partnerships or acquisitions.
- Positive financial results demonstrating improved profitability.
What Are the Key Risks for DLTNF?
- Financial-distress signal — its Altman Z-Score of -1.86 sits in the distress zone (elevated bankruptcy risk).
- Intense competition in the Canadian cannabis market.
- Evolving regulations and compliance requirements.
- Fluctuations in cannabis prices affecting revenue.
- Economic downturn reducing consumer spending on cannabis.
- Delays in regulatory approvals for new products or expansion plans.
What Are the Growth Opportunities for DLTNF?
- Expansion of Retail Footprint: Delta 9 can expand its retail presence beyond the Canadian Prairies to other provinces, increasing its market reach and revenue potential. The Canadian cannabis retail market is projected to reach several billion dollars in the coming years, offering significant growth opportunities for companies with established retail networks. The timeline for expansion depends on regulatory approvals and capital availability.
- Product Innovation and Diversification: Delta 9 can invest in research and development to create new and innovative cannabis products, catering to evolving consumer preferences. This includes developing new formulations, delivery methods, and product formats. The market for cannabis-infused products, such as edibles and beverages, is growing rapidly, presenting opportunities for Delta 9 to diversify its product portfolio. The timeline for product development and launch is typically 12-18 months.
- Strategic Partnerships and Acquisitions: Delta 9 can pursue strategic partnerships and acquisitions to expand its capabilities and market reach. This includes partnering with other cannabis companies, technology providers, or research institutions. Acquisitions can provide access to new markets, technologies, or product lines. The timeline for partnerships and acquisitions varies depending on the specific opportunities.
- International Expansion: Delta 9 can explore opportunities to expand its operations internationally, particularly in countries with legal cannabis markets. This includes exporting cannabis products, establishing joint ventures, or acquiring foreign cannabis companies. The global cannabis market is growing rapidly, offering significant long-term growth potential. The timeline for international expansion depends on regulatory approvals and market conditions.
- Medical Cannabis Focus: Delta 9 can focus on expanding its medical cannabis business, catering to patients seeking cannabis-based therapies. This includes developing new medical cannabis products, partnering with healthcare providers, and conducting clinical research. The medical cannabis market is growing steadily, driven by increasing awareness of the therapeutic benefits of cannabis. The timeline for medical cannabis initiatives depends on regulatory approvals and clinical trial results.
What Opportunities Does DLTNF Have?
- Expansion of retail footprint to other provinces.
- Product innovation and diversification.
- Strategic partnerships and acquisitions.
- International expansion.
What Threats Does DLTNF Face?
- Increasing competition in the Canadian cannabis market.
- Evolving regulations and compliance requirements.
- Fluctuations in cannabis prices.
- Economic downturn affecting consumer spending.
What Are DLTNF's Competitive Advantages?
- Integrated operations provide control over the entire value chain.
- Established retail presence in the Canadian Prairies.
- Proprietary grow pod technology.
- Delta 9 brand recognition.
What Does DLTNF Do?
Delta 9 Cannabis Inc., incorporated in 2001 and headquartered in Winnipeg, Canada, operates as an integrated cannabis company. Through its subsidiary, Delta 9 Bio-Tech Inc., the company cultivates, processes, extracts, and distributes cannabis products. Delta 9's operations span the entire cannabis value chain, from cultivation to retail sales. The company's product portfolio includes dried cannabis flowers, pre-rolls, decontamination pods, dried sift cannabis, oils, and extracted and derivative products. Delta 9 also provides grow pods and live plants to other licensed and pre-licensed cannabis companies. In addition to its product offerings, Delta 9 operates a medical clinic providing physician consultation services for patients seeking medical cannabis prescriptions. As of April 20, 2022, Delta 9 owned and operated 35 retail stores under the Delta 9 brand name across the Canadian Prairies, solidifying its presence in the regional cannabis market. Delta 9 continues to expand its retail footprint and product offerings to meet the evolving demands of the cannabis market.
What Products and Services Does DLTNF Offer?
- Cultivates cannabis plants in controlled environments.
- Processes raw cannabis into various product forms.
- Extracts cannabinoids to create oils and concentrates.
- Wholesales cannabis products to other licensed retailers.
- Operates retail stores under the Delta 9 brand.
- Sells medical and recreational cannabis products.
- Provides physician consultation services for medical cannabis prescriptions.
How Does DLTNF Make Money?
- Vertically integrated operations from cultivation to retail.
- Revenue generation through wholesale and retail sales of cannabis products.
- Medical clinic services providing cannabis prescriptions.
- Sales of grow pods and live plants to other licensed producers.
What Industry Does DLTNF Operate In?
Delta 9 Cannabis Inc. operates within the rapidly evolving Canadian cannabis industry. The market is characterized by increasing competition, evolving regulations, and shifting consumer preferences. Delta 9 competes with other licensed producers and retailers, vying for market share in both the medical and recreational cannabis segments. The Canadian cannabis market is expected to continue growing, driven by increasing legalization and acceptance of cannabis products. Companies like Delta 9 must adapt to changing regulations and consumer demands to remain competitive.
Who Are DLTNF's Key Customers?
- Recreational cannabis consumers.
- Medical cannabis patients with prescriptions.
- Other licensed cannabis retailers (wholesale).
- Licensed and pre-licensed cannabis companies (grow pods and live plants).
Company Profile
Delta 9 Cannabis Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Winnipeg, CA. The company is led by CEO John William Arbuthnot IV. DLTNF has traded publicly since 2017.
Delta 9 Cannabis Inc. (DLTNF) Valuation Context
Valued at $3.04M, DLTNF is classified as a micro-cap stock. Relative to its peer group, DLTNF's quantitative score of 42/100 is below the peer average of 66/100.
Key Financial Metrics
Return on assets is -23.6%, showing how much profit it generates from its asset base. A current ratio of 0.40 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 4/9Financial Health
Delta 9 Cannabis Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -1.86 places it in the distress zone, a signal of elevated financial risk.
DLTNF Financials
Bull Case vs Bear Case
Bull Case
- Integrated operations across the cannabis value chain.
- Established retail presence in the Canadian Prairies.
- Proprietary grow pod technology.
- Delta 9 brand recognition.
Bear Case
- Negative profit margin and gross margin.
- Limited geographic presence compared to larger competitors.
- Reliance on the Canadian cannabis market.
- Small market capitalization.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
DLTNF Latest News
No recent news available for DLTNF.
DLTNF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DLTNF.
Price Targets
Wall Street price target analysis for DLTNF.
DLTNF MoonshotScore
What does this score mean?
The MoonshotScore rates DLTNF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: John William Arbuthnot IV
CEO
John William Arbuthnot IV serves as the CEO of Delta 9 Cannabis Inc. His leadership is pivotal in guiding the company's strategic direction and operational execution. Information regarding his specific educational background and previous roles is not available. As CEO, he is responsible for overseeing all aspects of the company's operations, including cultivation, processing, distribution, and retail sales. He manages a workforce of approximately 200 employees.
Track Record: Under John William Arbuthnot IV's leadership, Delta 9 Cannabis Inc. has expanded its retail footprint to 35 stores across the Canadian Prairies. He has overseen the development and launch of new cannabis products and the implementation of the company's integrated business model. However, the company's financial performance has been challenged by negative profit margins.
DLTNF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Delta 9 Cannabis Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Lower trading volumes and liquidity.
- Potential for price volatility.
- Higher risk of fraud or manipulation.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal risks.
- Monitor trading volumes and price movements.
- Consult with a financial advisor.
- Understand the risks associated with OTC investing.
- Licensed cannabis producer and retailer in Canada.
- Operational retail stores under the Delta 9 brand.
- Presence in the cannabis industry since 2001.
- Integrated operations across the cannabis value chain.
Common Questions About DLTNF (Healthcare)
What does Delta 9 Cannabis Inc. do?
Delta 9 Cannabis Inc. is an integrated cannabis company operating in Canada. The company cultivates, processes, extracts, and distributes cannabis products through its subsidiary, Delta 9 Bio-Tech Inc. Delta 9's operations span the entire cannabis value chain, from cultivation to retail sales. The company's product portfolio includes dried cannabis flowers, pre-rolls, oils, and extracted products, catering to both medical and recreational markets. As of April 20, 2022, Delta 9 owned and operated 35 retail stores under the Delta 9 brand name across the Canadian Prairies.
What are the main risks for DLTNF?
The main risks for Delta 9 Cannabis Inc. include intense competition in the Canadian cannabis market, evolving regulations and compliance requirements, fluctuations in cannabis prices, and the potential for an economic downturn to reduce consumer spending on cannabis. The company's negative profit margin and gross margin also pose significant financial risks. Additionally, as an OTC-listed stock, DLTNF is subject to risks associated with limited financial disclosure, lower trading volumes, and potential price volatility.
What are the key factors to evaluate for DLTNF?
Delta 9 Cannabis Inc. (DLTNF) holds an AI score of 42/100 (low). Not financial advice.
How frequently does DLTNF data refresh on this page?
DLTNF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven DLTNF's recent stock price performance?
Delta 9 Cannabis Inc. (DLTNF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Integrated operations across the cannabis value chain. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider DLTNF overvalued or undervalued right now?
Valuing Delta 9 Cannabis Inc. (DLTNF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying DLTNF?
Before investing in Delta 9 Cannabis Inc. (DLTNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding DLTNF to a portfolio?
Key strength of Delta 9 Cannabis Inc. (DLTNF): Integrated operations across the cannabis value chain. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited.
- OTC stocks are inherently riskier than exchange-listed stocks.